» Articles » PMID: 29873812

Alcohol Consumption and Bone Mineral Density in People with HIV and Substance Use Disorder: A Prospective Cohort Study

Abstract

Background: People living with HIV (PLWH) commonly have low bone mineral density (BMD) (low bone mass and osteoporosis) and are at high risk for fractures. Fractures and low BMD are significant causes of morbidity and mortality, increasingly relevant as PLWH age. Alcohol use is common among PLWH and known to affect bone health. The association between alcohol use and changes in BMD among PLWH is not well understood.

Methods: We conducted a 3.5-year prospective cohort study of 250 PLWH with substance use disorder or ever injection drug use. Annual alcohol consumption was measured as a mean of grams per day of alcohol, mean number of heavy drinking days per month, mean number of days abstinent per month, and any heavy drinking, using the 30-day Timeline Followback method twice each year. The primary outcome was annual change in BMD measured each year by dual energy X-ray absorptiometry in grams per square centimeter (g/cm ) at the femoral neck. Additional dependent variables included annual change in total hip and lumbar spine BMD, >6% annual decrease in BMD at any site, and incident fractures in the past year. Regression models adjusted for relevant covariates.

Results: The median age of participants was 50 years. The median duration of HIV infection was 16.5 years and the mean time since antiretroviral therapy initiation was 12.3 years. At study entry, 67% of participants met criteria for low BMD (46% low bone mass, 21% osteoporosis). Median follow-up was 24 months. We found no significant associations between any measure of alcohol consumption and changes in BMD (g/cm ) at the femoral neck (adjusted β for g/d of alcohol = -0.0032, p = 0.7487), total hip, or lumbar spine. There was no significant association between any measure of alcohol consumption and >6% annual decrease in BMD at any site, or incident fractures.

Conclusions: In this sample of PLWH and substance use disorders or ever injection drug use, we detected no association between any of the alcohol measures used in the study and changes in BMD or incident fractures.

Citing Articles

Bone Tissue Changes in Individuals Living with HIV/AIDS: The Importance of a Hierarchical Approach in Investigating Bone Fragility.

Jadzic J, Dragovic G, Lukic R, Obradovic B, Djuric M J Pers Med. 2024; 14(8).

PMID: 39201983 PMC: 11355540. DOI: 10.3390/jpm14080791.


Bone Disease in HIV: Need for Early Diagnosis and Prevention.

Schinas G, Schinas I, Ntampanlis G, Polyzou E, Gogos C, Akinosoglou K Life (Basel). 2024; 14(4).

PMID: 38672792 PMC: 11051575. DOI: 10.3390/life14040522.


Self-medication of pain and discomfort with alcohol and other substances by people with HIV infection and substance use disorder: preliminary findings from a secondary analysis.

Stein M, Godersky M, Kim T, Walley A, Heeren T, Winter M AIDS Care. 2023; 36(3):414-424.

PMID: 37909062 PMC: 10922286. DOI: 10.1080/09540121.2023.2275047.


Cannabis use frequency and pain interference among people with HIV.

Klepp T, Heeren T, Winter M, Lloyd-Travaglini C, Magane K, Romero-Rodriguez E AIDS Care. 2023; 35(8):1235-1242.

PMID: 37201209 PMC: 10332422. DOI: 10.1080/09540121.2023.2208321.


Alcohol Consumption and Risk of Fractures: A Systematic Review and Dose-Response Meta-Analysis of Prospective Cohort Studies.

Ke Y, Hu H, Zhang J, Yuan L, Li T, Feng Y Adv Nutr. 2023; 14(4):599-611.

PMID: 36966875 PMC: 10334160. DOI: 10.1016/j.advnut.2023.03.008.


References
1.
Rey D, Treger M, Sibilia J, Priester M, Bernard-Henry C, Cheneau C . Bone mineral density changes after 2 years of ARV treatment, compared to naive HIV-1-infected patients not on HAART. Infect Dis (Lond). 2014; 47(2):88-95. DOI: 10.3109/00365548.2014.968610. View

2.
Cotter A, Sabin C, Simelane S, Macken A, Kavanagh E, Brady J . Relative contribution of HIV infection, demographics and body mass index to bone mineral density. AIDS. 2014; 28(14):2051-60. DOI: 10.1097/QAD.0000000000000353. View

3.
Carr A, Grund B, Neuhaus J, Schwartz A, Bernardino J, White D . Prevalence of and risk factors for low bone mineral density in untreated HIV infection: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015; 16 Suppl 1:137-46. PMC: 4341957. DOI: 10.1111/hiv.12242. View

4.
Gill U, Zissimopoulos A, Al-Shamma S, Burke K, McPhail M, Barr D . Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk?. J Infect Dis. 2014; 211(3):374-82. DOI: 10.1093/infdis/jiu471. View

5.
Manolagas S, Kousteni S, Jilka R . Sex steroids and bone. Recent Prog Horm Res. 2002; 57:385-409. DOI: 10.1210/rp.57.1.385. View